ALNFL Share Price Performance
€1.33
-0.57 (-30.01%)
Price €1.33
Share Pricen/a
NFL Biosciences SA Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
ALNFL Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
NFL Biosciences SA Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -0.25
- -942,775.61%
- -1,922,592.07%
- 4.2%
About ALNFL
- Founded
- 2006
- Employees
- 5
- CEO
- WebsiteView website
NFL Biosciences SA, a biotechnology company, engages in the development of botanical drugs in France. The company’s pipeline includes NFL-101, a drug candidate for smoking cessation, currently under Phase 2b clinical trials; and NFL-301, a drug candidate for reducing alcohol consumption which is in preclinical stage. It has scientific collaboration with McLean Hospital to deepen the understanding of the mechanism of action of NFL-101, its proprietary botanical drug candidate for smoking cessation. NFL Biosciences SA was incorporated in 2006 and is headquartered in Castelnau-le-Lez, France.
